Shanghai Junshi Biosciences (HKG:1877) reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.
Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.
The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.